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Profilin-1 (Pfn1 - a ubiquitously expressed actin-binding protein) levels are significantly 
downregulated in various invasive adenocarcinomas including breast cancer. Although Pfn1 has 
been shown to be required for motility for most normal cells, breast cancer cells and normal 
human mammary epithelial cells exhibit a hypermotile phenotype upon Pfn1 depletion, and re-
expression of Pfn1 in breast cancer cells decreases their migration. The traditionally conceived 
pro-migratory function of Pfn1 through its relatively well-studied interactions with actin and 
polyproline ligands does not provide guidance to explain this context-specific effect of Pfn1 on 
cell migration. The overall goal of this study is to reveal molecular mechanisms underlying the 
hypermotile phenotype of breast cancer cells as a result of Pfn1 downregulation. We first show 
that loss of Pfn1 expression increases motility of breast cancer cells by enhancing targeting of 
Ena(enabled)/VASP (vasodilator stimulated phosphoprotein) family of actin-binding proteins to 
the leading edge, a feature that is also reproducible in other cells. We further demonstrate that 
Ena/VASP targeting to the leading edge is mediated through the action of lamellipodin (Lpd - a 
membrane anchoring protein) and Pfn1 negatively regulates membrane targeting of Lpd. 
Limiting Lpd expression impairs motility of Pfn1-deficient breast cancer cells, thereby 
demonstrating loss of Pfn1 augments breast cancer cell motility through enhanced membrane 
recruitment of VASP/Lpd complex. Subsequent rescue experiments with various ligand-binding 
deficient mutants of Pfn1, we further demonstrate that Pfn1 inhibits breast cancer cell motility 
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mainly by its phosphoinositide interaction through negative regulation of Lpd/VASP targeting to 
the leading edge. Membrane targeting of Lpd in Pfn1-deficient breast cancer cells critically 
depends on the availability of D3-phosphorylated phosphoinositides, and consistent with this 
observation, we demonstrate that loss of Pfn1 expression significantly increases PI(3,4)P2 
presentation at the leading edge. Collectively, these findings identify a novel inhibitory 
mechanism of Pfn1 on breast cancer cell motility by regulating membrane availability of 
PI(3,4)P2 and docking of Lpd, and this involves Pfn1’s phosphoinositide interaction. This is in 
contrast to conventionally thought Pfn1’s regulation of cell motility primarily through its 
interactions with actin and polyproline ligands. 
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1.0  INTRODUCTION 
1.1 BREAST CANCER AND ITS METASTASIS 
Breast cancer, the most commonly diagnosed non-skin cancer in women, is currently the second 
leading cause of cancer-related deaths in the United States with an estimated 40,610 deaths 
anticipated in the year 2009 [Welch et al., 2000; Cancer facts and Figures 2009, the American 
Cancer Society]. The vast majority of these cancer deaths are due to metastasis of invasive breast 
carcinomas to several non-adjacent organs (bone, liver, lung, and kidney) in the body resulting in 
cancer death. When breast cancer cells are confined within the basement membrane barrier of 
mammary tissue (non-invasive tumor), the patient survival rate exceeds 90% because benign 
tumors can be removed by surgery [Sainsbury et al., 2000]. However, once breast tumor cells 
metastasize, especially to the internal organs and the brain, morbidity and mortality rate 
increases drastically. A significant percentage of advanced breast cancer patients suffer from 
bone metastasis, which results in the resorption of bone, and eventually leads to osteoporosis, 
spinal cord compression, and fracture of long bones. As a result, the quality of life of these 
patients becomes severely comprised. Thus, elucidation of underlying cellular mechanisms of 
cancer metastasis and identification of molecular targets that inhibit tumor metastasis are 
critical for developing effective anti-metastatic therapeutics for breast cancer patients. Such 
therapeutic interventions should have a remarkable impact on not only controlling numerous 
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metastatic cancers but also improving the survival rate and the quality of life of both early stage 
and advanced breast cancer patients. 
 
 
Figure 1: A schematic illustration of tumor metastasis 
 
Chiang et al. stated that “Metastasis is the end product of an evolutionary process in 
which diverse interactions between cancer cells and their microenvironment yield alterations 
that allow these cells to transcend their programmed behavior” [Chiang et al., 2008]. Metastatic 
breast cancer cells from the primary tumor at the luminal epithelial lineage of terminal duct 
lobular units of the breast initiate by genetic alterations, thereby, these tumor cells are able to 
acquire new functions for metastatic potentials which facilitate their propagation to distant 
regions [Petersen et al., 2001; Chiang et al., 2008]. Distant metastasis of tumor is a multi-stage 
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process (schematically represented in Fig 1) and involves numerous signaling pathways. 
Metastasis of breast cancer is critically dependent on neovascularization (angiogenesis) in the 
tumor which provides a route for distant metastasis [Schneider et al., 2005].  To metastasize, 
aggressive malignant cells, which have lost the ability to adhere with their adjacent cells, 
dissociate from the localized primary tumor site and penetrate the surrounding connective tissue 
by breaking the dense basement membrane [BASAL LAMINA DEGRADATION AND 
INVASION]. Next, these disseminated tumor cells secrete factors that promote vascular 
endothelial cell contraction which causes retraction of the cell-cell junctions and impairs 
endothelial cell barrier function by creating gaps between endothelial cells so that cells can enter 
blood microvessels (hematogenous dissemination) or the lymphatic routes (lymphatic 
dissemination) [INTRAVASATION]. These cancer cells are transported through circulation to 
distant secondary sites where they may be trapped and subsequently leave the vasculature to 
enter the secondary target site [EXTRAVASATION]. Then, tumor cells invade to normal 
surrounding tissue and form dormant micrometastases. Eventually some of micrometastases 
proliferate and form solid macroscopic metastases in the secondary target organ [Enger et al., 
2000; Wyckoff et al., 2000; Lambrechts et al., 2004]. One of the essential steps of the tumor 
metastasis to other sites is cell invasion to adjacent connective matrix, which requires active cell 
migration. At the molecular level, cancer cell migration is correlated with deregulated actin 
cytoskeleton.  
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1.2 DEREGULATION OF ACTIN CYTOSKELETON SIGNALING IN CANCER 
CELL MIGRATION 
Cell motility (schematically represented in Figure 2), a fundamental aspect of cancer invasion 
and metastasis, requires an asymmetry of biophysical and mechanical cell processes in a cyclic 
nature [Yamaguchi et al., 2005; Feldner et al., 2002; Lauffenburger et al., 1996]. Thus, dissecting 
molecular mechanisms of cell migration is an indispensable first step in understanding the 
behavior of cancer cells, thereby, preventing or limiting the invasion and metastasis of cancer. 
 
 
Figure 2: A schematic illustration of cell migration [modified from (Ridley et al., 2003)] 
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In order for cell migration to occur, actin cytoskeletal reorganization in cells is a 
prerequisite to protrude their leading edge and to generate contractility that directed to net cell 
movement. Actin dynamics in motile cells is regulated by a large number of actin-binding 
proteins (ABPs) including those engaged in G-actin sequestering (thymosin β4), nucleation of 
actin filaments (Arp2/3, WASP, formin), elongation of actin filaments (Ena/VASP, formin), 
nucleotide exchange on G-actin and shuttling of G-actin to barbed ends of growing actin 
filaments (profilin), capping (capZ), severing/depolymerization (actin depolymerizing factor 
(ADF)/cofilin, gelsolin), and cross-linking/stabilization (filamin, fascin, cortactin) [Pollard et al., 
2003; Roy et al., 2008]. Disruption of actin cytoskeleton is a characteristic of malignant cells, 
and this correlates with altered expression and/or activity of wide-range of ABPs [Roy et al., 
2008; Clark et al., 2000; Wang et al., 1996].  
To migrate/invade to connective tissues and infiltrate into blood vessels, cells are initially 
required to polarize by migration-promoting molecules or microenvironments that include 
motogenic agents (growth factors such as EGF (epidermal), PDGF (platelet-derived), and VEGF 
(vascular endothelial)), chemokines (chemotactic cytokines that include four subfamilies; C, CC, 
CXC, and CX3C, (C: a cysteine; X: any amino-acid residue)  [Rottman et al., 1999]), cytokines 
(secreted molecules that signal through G-protein-linked receptors), and extracellular matrix 
(ECM) [Huttenlocher et al., 2005]. In response to migration stimuli, cells subsequently extend 
their lamellipodia (flat, sheet-like membrane network of actin filaments) or filopodia (thin, spike-
like cytoplasmic projection) for leading membrane protrusions in a given direction due to 
enhanced actin polymerization at the cell’s front. Once the migration path is defined, the 
protrusive machinery for facilitating movement assembles with regard to the directional 
migration. Membrane modifying enzymes that are associated with  the inner membrane surface 
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(example: phospholipase C-γ (PLCγ) and phosphatidylinositol 3-kinase (PI3K)) are activated at 
the downstream of various receptor tyrosine kinases (RTKs) such as a induce actin cytoskeletal 
reorganizations by altering membrane docking phospholipid-binding ABPs (profilin, cofilin, 
capping protein, and gelsolin) [Roy et al., 2008; Rheenen et al, 2007]. These ABPs in turn 
regulate actin meshwork at the cell’s leading edge by modulating actin turnover [Pollard et al, 
2003; Chen et al., 1996; Janmey et al., 1994; Allen et al., 2003; Goldschmidt-Clermont et al., 
1991; Bae et al., 2006]. 
Next, cells create new focal adhesions to ligands (collagen, fibronectin, laminin, and 
fibrinogen) in the ECM (the basal lamina, connecting fibers, connective tissue) or to molecules 
(cadherins) on the surface of adjacent cells through the binding of transmembrane receptors 
(integrins; a family of αβ heterodimers) which are linked with intracellular molecules (actinin, 
talin, vinculin, and filamin) that bind intracellular actin filaments inside. All of this acts to 
stabilize the dominant protruding lamellipodia at the leading edge of the cell membrane [Ridley 
et al., 2003; Sheetz et al., 1999; Roy et al., 2008]. In addition to ECM components, integrins 
attach to a cytoplasmic complex such as focal adhesion kinases (FAK) and Src family kinases to 
mediate adhesion to the actin cytoskeleton. 
The cell-substratum attachment is followed by de-adhesion and retraction at the rear end 
of the cell, but the leading edge stays attached to the ECM. These final processes require myosin 
II (an actin-based motor protein in eukaryotic non-muscle cells)-based contraction of actin 
filaments which generate a sufficient amount of force/tension, to provide forward movement of 
the cell [Sheetz et al., 1999]. Movement over an extended distance occurs through many 
repetitions of this cycle in a directionally-persistent manner. The forward protrusion by actin 
polymerization establishes the directionality and protrusive force of the cell, even in the absence 
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of a signaling gradient [Sheetz et al., 1999; Roy et al., 2008]. Overall, acquisition of the invasive 
phenotype by malignant cells is correlated with active reorganization of the actin cytoskeleton by 
deregulated expression of various ABPs [Feldner et al., 2002; Pawlak et al., 1999]. The 
malignant phenotype of tumor cells often can be reversed by experimental restoration of ABP 
expression, signifying that misregulation of ABPs could contribute directly to malignancy 
[Nikolopoulos et al., 2000; Tanaka et al., 1995]. Consistent with these findings, reduced 
expression of profilin-1 (Pfn1- an important actin regulatory protein) has been reported in 
various invasive adenocarcinomas including breast cancer cell. Whether there is any fundamental 
link between reduced Pfn1 expression and increased aggressiveness of various adenocarcinoma 
remains to be determined. 
 
1.3 PROFILIN-1 BIOCHEMISTRY 
Presently, four different mammalian profilin genes have been identified: Pfn1 (a member of 
profilin that is ubiquitously expressed in all cell types except skeleton muscle tissue [Witke et al., 
1998]), Pfn2 (has two splice variants [Pfn2a and Pfn2b] which are mainly expressed in the cells 
of  neural tissues [Witke et al., 1998; Giesemann et al., 1999]), Pfn3 (expression restricted to t 
kidney and testis) and Pfn4 (expression limited to testis) [Lambrechts et al., 2000; Hu et al., 
2001; Obermann et al., 2005]). From here, only Pfn1 will be reviewed and discussed in my thesis 
because of its implications in cancer. Pfn1 is capable of interacting mainly with three classes of 
ligands including actin monomers, many proline-rich proteins and various polyphosphoinositides 
[Fedorov et al., 1994; Metzler et al., 1994; Chaudhary et al., 1998; Mahoney et al., 1999]. Pfn1 
was initially reported as a G-actin sequestering protein [Karlsson et al., 1977].  
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Figure 3: Pfn1’s role in actin polymerization [modified from (Witke et al., 2004)] 
 
However, subsequent studies revealed that one of the major roles of Pfn1 is to promote actin 
polymerization in cells (schematically represented in Figure 3) by 1) accelerating the nucleotide 
exchange rate of ADP-to-ATP on G-actin, and 2) transporting ATP-G-actin to the free and fast-
growing barbed ends of actin filaments [Karlsson et al., 1977; Pantaloni et al., 1993; Kang et al., 
1999; Schluter et al., 1997; Bubb et al., 2003; Goldschmidt-Clermont et al., 1990; Witke et al., 
2004]. 
Besides actin, Pfn1 also associates with a number of proline-rich proteins (PLP) that 
control actin assembly by promoting either nucleation and/or elongation of actin filaments at the 
leading edge, including proteins belonging to the Ena (enabled)/VASP (vasodilator stimulated 
phosphoprotein) [Ferron et al., 2007], N-WASP (Neural Wiskott Aldrich syndrome protein; the 
ubiquitously expressed member of WASP [Suetsugu et al., 1998]), WAVE (WASP family 
verprolin-homologous protein [Miki et al., 1998]), and diaphanous [Miki et al., 1998; Watanabe 
et al., 1999] protein families. Limiting Pfn1 expression resulting in slightly decreased total F-
actin level in various cells is consistent with this actin-regulatory function of Pfn1 [Ding et al., 
2006; Zou et al., 2007; Ding et al., 2009] . It has been proposed that these extracellularly-
activated PLP may potentially act as molecular scaffolds to spatially recruit the Pfn1-actin 
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complex to sites of actin assembly at the leading edge during active cell migration [Holt et al., 
2001]. 
In addition to actin and PLP ligands (proteins containing polyproline domains), Pfn1 also 
binds to plasma membrane most likely through its interactions with various phosphoinositides 
(PPIs) including phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2), phosphatidylinositol-3,4-
bisphosphate (PI(3,4)P2; generated by dephosphorylation of PIP3 by PI-5-phosphatase) and 
phosphatidylinositol-3,4,5-triphosphate (PIP3; generated by the phosphorylation of PI(4,5)P2 by 
PI3K) [Lu et al., 1996], potentiating it as a mediator between the cell membrane and 
cytoskeleton [Machesky et al., 1993]. PI(3,4)P2 and PIP3 are generated by activation of 
phosphoinositide 3-kinase (PI3K) and have a greater binding affinity to profilin than PI(4,5)P2 
[Lu et al., 1996]. Mammalian Pfn1 has two PPI binding regions, one largely overlapping with its 
actin-binding site and the other partially overlapping with its PLP binding site. It has been 
suggested that Pfn1 binding to PPI mostly inhibits its interaction with actin [Skare et al., 2002; 
Lassing et al., 1985]. 
Among the different ligand-binding abilities of Pfn1, the actin and PLPs interactions have 
been most heavily investigated in the literature, mainly in the context of cytoskeletal regulation. 
However, very little known about Pfn1’s interaction with membrane PPIs which has been almost 
exclusively investigated in vitro using pure protein-phospholipid mixture [Goldschmidt-
Clermont et al., 1990] and therefore, physiological and pathological implications of Pfn1’s 
interaction with membrane PPIs has not been explored in vivo. Signaling events downstream of 
PPIs play a major role in cell motility. However, whether Pfn1’s interactions with various 
membrane phospholipids have any modulatory function on cell migration has not been 
investigated in depth. Although it remains to be investigated, based on Pfn1’s ability to inhibit 
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PLC-mediated PI(4,5)P2 hydrolysis in vitro [Goldschmidt-Clermont et al., 1990] and a recent 
study by our group directly showing for the first time that significant suppression of PIP3 
generation in Pfn1-overexpressed breast cancer cells [Das et al., 2009], one could envision that 
Pfn1 may regulate membrane PPI metabolism by posing steric hindrance to some docking 
proteins and metabolic enzymes of PPIs through competition for lipid binding and in turn affect 
cell motility. Since these in vitro (using purified proteins and lipid micelles) and in vivo (using 
Pfn1 overexpression system in breast cancer cells) studies could not thoroughly show Pfn1’s 
interaction with specific PPI cellular processes in detail, Pfn1’s role in PPI metabolism and its 
functional significance needs to be revisited in a cellular context.    
   
1.4 PROFILIN-1’S ROLE IN NORMAL AND CANCER CELL MIGRATION 
Numerous previous studies identify Pfn1 as an important actin-binding protein in the overall 
balance of actin polymerization in cells. However, its exact role in cell migration has not been 
well understood until recently. The first direct evidence of Pfn1’s role in cell migration is from a 
study on Dictyostelium amebae mutants deficient in both Pfn1 and Pfn2, which demonstrated 
considerably impaired cytokinesis and cell motility [Haugwitz et al., 1994]. In addition, 
Drosophila harboring Pfn1-mutants exhibited developmental defects [Verheyen et al., 1994]. 
Profilin is necessary for motor axon outgrowth in the Drosophila Embryo [Wills et al., 1999] and 
C. elegans requires Pfn1 function for embryogenesis [Velarde et al., 2007]. Dependence of actin-
driven intracellular propulsion of bacterial pathogens on Pfn1 (Loisel et al., 1999; Mimuro et al., 
2000), impaired membrane protrusion of HUVECs (Human vascular endothelial cells) as a result 
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of Pfn1 downregulation [Ding et al., 2006], and very recently, induction of lamellipodia by Pfn1 
in a growth-factor insensitive mechanism [Syriani et al., 2008] all point to a key role of Pfn1’s 
function in driving membrane protrusion during most normal cell migration. In addition, studies 
by our group showed that both actin and PLP interactions of Pfn1 contribute to membrane 
protrusion and overall cell migration at least for vascular endothelial cell lines [Ding et al., 2006; 
Ding et al., 2009]. Collectively, these experimental evidences suggest that Pfn1 is a critical 
prerequisite molecule for normal cell migration and development. 
Interestingly however, significant reduction of Pfn1 expression has been shown in 
various types of highly invasive adenocarcinoma (a cancer originating in glandular epithelial 
tissue including breast, pancreatic, hepatic, and gastric) when compared to their non-tumorigenic 
counterparts [Gronborg et al., 2006; Janke et al., 2000; Wu et al., 2006; Oien et al., 2003]. A 
moderate overexpression of Pfn1 in CAL51 (epithelial, human breast carcinoma) and MDA-231 
breast cancer cell lines significantly inhibits its tumorigenic potential in nude mice [Janke et al., 
2000; Wittenmayer et al., 2004; Roy et al., 2004; Zou et al., 2007] suggesting that Pfn1 could be 
a tumor-suppressor protein as well. These experimental data are also consistent with 
immunohistological findings of graded Pfn1 downregulation with increased cancer grade [Janke 
et al., 2000]. Similarly, retinoic acid-induced suppression of hepatocarcinoma cell migration can 
be reversed by downregulating Pfn1 [Wu et al., 2006].  Previous studies from our lab show that 
loss of Pfn1 expression results in increased motility of both normal human mammary epithelial 
cells (HMEC) and MDA-231 breast cancer cells [Zou et al., 2007]. Conversely, restoring Pfn1 
levels by overexpression significantly impairs the aggressive phenotype of breast cancer cells 
(Roy et al., 2004; Zou et al., 2007). Collectively, these findings raises a possibility that Pfn1 
downregulation could lead to increased breast cancer invasion and metastasis in vivo. However, 
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given the plethora of evidence demonstrating importance of Pfn1 in driving actin polymerization 
at the leading edge and hence playing a critical role in cell migration, the existing literature fails 
to explain how loss of Pfn1 expression might contribute to enhanced motility of breast cancer 
cells at a mechanistic level. The overall goal of my research is to elucidate molecular 
mechanisms underlying the hypermotile phenotype of breast cancer cells as a result of Pfn1 
downregulation. 
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2.0  HYPOTHESIS AND SPECIFIC AIMS 
Given the generally considered pro-migratory role of Pfn1 mediated primarily through its actin 
and polyproline interactions, the existing studies cannot intuitively elucidate how loss of Pfn1 
expression augments carcinoma cell motility. My preliminary studies demonstrate that loss of 
Pfn1 expression enhances lamellipodial targeting of Ena/VASP proteins in several different cell 
lines including HUVEC, HMEC and MDA-231cells [Bae et al., 2009]. It has been recently 
shown that fish keratocytes (an extremely fast migrating epithelial cell type) migrate faster and in 
a smooth, gliding fashion when Ena/VASP family proteins are enriched at their leading edge 
[Lacayo et al., 2007]. Leading edge targeting of Ena/VASP has also been shown to result in 
faster membrane protrusion [Bear et al., 2002]. Recent studies further show that Ena/VASP 
proteins play a major role in chemotactic invasion of breast cancer cells [Philippar et al., 2008]. 
Lamellipodin (Lpd), a member of MRL (Mig10/ Rap1-interacting adaptor molecule / 
lamellipodin) family of actin-binding proteins which contain a pH domain with binding 
specificity PI(3,4)P2, has been identified as one of the potential linker for targeting Ena/VASP 
close to the plasma membrane at the leading edge. Herein, I postulate that limiting Pfn1 
expression in breast cancer cells enhances D3-phosphoinositide (such as PI(3,4)P2) 
presentation at the leading edge of migrating cells, allows increased access of lamellipodin to 
the plasma membrane and creates a hypermotile phenotype.  
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To test the overall hypothesis, I proposed the following aims:  
Specific Aim1: To determine whether VASP plays a role in the hypermotile response of 
breast cancer cells induced by loss of Profilin-1 expression.  
 
Specific Aim2: To examine whether Profilin-1 inhibits breast cancer cell motility by 
regulating D3-phosphoinositide availability for lamellipodin targeting to the membrane. 
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3.0  MATERIALS AND METHODS 
3.1 ANTIBODIES AND REAGENTS 
Polyclonal Pfn1 and GAPDH antibodies were purchased from Cytoskeleton (Denver, CO- in 
some experiments, a different polyclonal Pfn1 antibody that was kindly provided by Dr. Sally 
Zigmond of the University of Pennsylvania was used) and Abd Serotec (Raleigh, NC), 
respectively. Polyclonal GFP and monoclonal VASP antibodies was obtained from Pharmingen 
(San Diego, CA). Polyclonal Lpd antibody was purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA- in some experiments, a different polyclonal Lpd antibody that was supplied by 
Dr. Frank Gertler of the Massachusetts Institute of Technology was used). Polyclonal cofilin 
antibody was purchased from Abcam (Cambridge, MA). Monoclonal PI(3,4)P2 antibody was 
obtained from Echelon Biosciences (Salt Lake City, Utah). Polyclonal EGFR, AKT and 
phospho-AKT (S473) antibodies are products of Cell Signaling Technology (Danver, MA). 
Polyclonal PDGFR-β antibody was kindly provided by Dr. Paul Monga (University of 
Pittsburgh). Monoclonal phosphotyrosine and phospho-EGFR (Y1173) antibodies were obtained 
from Upstate Biotechnology (Billerica, Massachusetts). All cell culture reagents are products of 
Invitrogen (Carlsbad, CA). PI3-kinase inhibitor LY294002 was purchased from Calbiochem 
(Carlsbad, CA). Cytochalasin-D was purchased from Cytoskeleton, Inc. (Denver, CO). Plasmids 
encoding Ena/VASP sequestration (FP4-mito) and corresponding control (AP4-mito) constructs 
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were generated in Dr. Gertler’s laboratory as previously described [Bear et al., 2000; Bear et al., 
2002] and subsequently subcloned in mCherry vector. Expression vectors for GFP-PTEN and 
GFP-PH-AKT were generously provided by Drs. Pier Pandolfi (Beth Israel Deaconess Medical 
Center) and Tamas Balla (National Institute of Health), respectively. The sequences of Control 
and Pfn1 siRNAs have been previously described [Bae et al., 2009]. A pool of Lpd siRNAs was 
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). 
3.2 CELL CULTURE AND TRANSFECTION 
MDA-231 breast cancer cells were cultured in EMEM media (supplemented with 10% FBS, 
sodium pyruvate and antibiotics (Invitrogen - Carlsbad, CA). HMEC and HUVEC (source: 
Cambrex, Walkersville, MD) were cultured in a complete growth media supplied by the 
manufacturer. All Pfn1 constructs were generated by site-directed mutagenesis and rendered 
Pfn1-siRNA-resistant by introducing silent mutation in the siRNA targeting region without 
changing their peptide encoding (targeting region of Pfn1-siRNA has been previously described 
[Bae et al., 2009]). MDA-231 cells stably transfected with various Pfn1 constructs (using 
lipofectamine 2000 reagent (Invitrogen- Carlsbad, CA) were maintained in complete growth 
media supplemented with 500 μg/ml G418. The working concentration for various siRNAs were: 
Pfn1 (50 nM for MDA-231, 100 nM for HUVEC and HMEC) and Lpd (100 nM). SiRNA 
transfection was performed using reagents commercially available from Dharmacon (Lafayette, 
CO) according to the manufacturer’s instruction and all silencing-based experiments were 
performed 72 hours after transfection.  
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3.3 IMMUNOSTAINING 
Cells were washed with DPBS, fixed with 3.7% formaldehyde for 15 minutes, permeabilized 
with 0.5% Triton X-100 for 15 minutes and then blocked with 10% goat-serum for 1 hour at 
room temperature. After incubating with the primary antibodies (VASP and/or Lpd at 1:100 
dilution; Pfn1 antibody at 1:50 dilution) for 1 hour at room temperature, cells were washed two 
times with DPBS containing 0.02% tween and 2 times with DPBS and then incubated with 
secondary antibodies (source: Jackson Immunoresearch, West Grove, PA) with or without alexa-
488 phalloidin (Invitrogen) for an additional hour at room temperature. Stained cells were 
washed two times with DPBS containing 0.02% tween, two times with DPBS, and then once 
with distilled water before mounting on slides for imaging using a 60X oil-immersion objective 
on an Olympus IX71 inverted microscope. Quantitative fluorescence analyses of images were 
performed by Metamorph or ImageJ. Specifically, for VASP and Lpd quantification at the 
leading edge, images were first background subtracted (the average intensity of cell-free area on 
the coverslips was used for background correction), and the average fluorescence intensity at the 
very leading edge (identified by phalloidin counterstaining) was then calculated based on 15-20 
line scan measurements across the lamellipodia. 
3.4 PI(3,4)P2 IMMUNOSTAINING AND QUANTIFICATION 
Cells were serum-starved for 30-40 hours and then stimulated with either EGF or PDGF 
(working concentration -100 ng/ml) for 30 minutes before performing PI(3,4)P2 immunostaining 
according to a previously described protocol [Yip et al., 2008]. Briefly, cells were fixed and 
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permeabilized with 3.7% paraformaldehyde and 0.1% glutaraldehyde in 0.15 mg/ml saponin 
solution for 1 hour at 37°C. Cells were incubated with anti-PI(3,4)P2 antibody diluted in PBS-5% 
BSA (1:200) for 1 hour, after which they were washed 4 times with PBS, incubated with 
rhodamine-conjugated secondary antibody for 45 minutes and washed again 4 times in PBS 
before mounting for microscopy. Images were acquired with a 60X objective on an Olympus 
Fluoview 1000 inverted confocal microscope and were background subtracted before 
quantitative fluorescence intensity analyses. For PI(3,4)P2 quantification at the leading edge, the 
average fluorescence intensity was then be quantitated based on 10 line scan measurements 
across the lamellipodia. These values were then normalized with respect to the average 
fluorescence value calculated for control-siRNA treated cells in serum-starved condition. 
3.5 PROTEIN EXTRACTION AND IMMUNOBLOTTING 
Total cell lysate (TCL) was prepared by extracting cells with warm 1X sample buffer or 
modified RIPA buffer (50 mM Tris-HCl - pH 7.5, 150 mM NaCl, 1% NP-40, 0.25% sodium  
deoxycholate, 0.3% SDS, 2 mM EDTA) supplemented with 50mM NaF, 1mM sodium 
pervanadate, and protease inhibitors (10 µg/ml of leupeptin, aprotinin, pepstatin and 1 mM 
phenylmethylsulfonyl fluoride). For sub-cellular fractionation analyses of GFP-Pfn1, cells were 
washed twice with cold PBS and extracted with 0.5% saponin in hypotonic buffer (10mM 
HEPES, pH7.9, 10mM KCl, 0.1mM EDTA, 1mM DTE with protease and phosphatase 
inhibitors) for 10 minutes to obtain the cytosolic fraction. Further extraction with 1% Triton-
X100 in hypotonic buffer for 15 min followed by clarification of the extract at 18000g for 15 
minutes yielded the membrane fraction. For immunoblotting, protein concentration was first 
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determined by a coomassie-based protein assay kit. Proteins separated with SDS-PAGE were 
transferred onto a nitrocellulose membrane. After blocking the membrane with the appropriate 
blocking solution in TBST for 1 hour at room temperature, immunoblotting was performed by 
overnight incubation at 4℃ with the appropriate primary antibodies. The antibodies were used at 
the following concentrations: GAPDH (1:2000), Pfn1 (1:500), VASP (1:1000), GFP (1:1000), 
cofilin (1:3000), Lpd (1:1000), AKT (1:500), phospho-AKT (1:500), EGFR (1:1000), phospho-
EGFR (1:200), PDGFR-β (1:200), and pY-PDGFR (1:1000). After washing 5 times with TBST, 
the blot was incubated with the appropriate secondary antibody, washed 4 times with TBST and 
finally once with distilled H2O before performing chemiluminescence for visualizing protein 
bands.  
3.6 FLUORESCENCE BASED F-ACTIN QUANTIFICATION 
Cellular level of F-actin was quantitated using a rhodamine-phalloidin binding assay as 
previously described [Diakonova et al., 2002]. Cells (3.6x105) were seeded in 2-3 replicates in 
the wells of a collagen-coated 6-well plate. After 4 hours of incubation, cells were fixed with 
3.7% formaldehyde for 15 min, permeabilized with 0.5% Triton X-100, and then co-stained with 
rhodamine-phalloidin and DAPI (for normalization of cell number) for 1 hour at room 
temperature. After washing cells three times with PBS, rhodamine-phalloidin was extracted with 
500 μl of methanol for 1 hour in the dark; cells were finally extracted with 300 μl of lysis buffer. 
Fluorescence readings of rhodamine (excitation 540 nm, emission 575 nm) and DAPI (excitation 
358 nm, emission 461 nm) were acquired using a spectrofluorometer and the ratio of rhodamine 
to DAPI fluorescence was calculated. 
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3.7 TIME-LAPSE CELL MOTILITY AND KYMOGRAPH ASSAYS 
Cells, sparsely plated overnight on collagen-coated 35-mm culture dish, were imaged for 2-3 h at 
a 1-min time-interval between the successive image frames. For all time-lapse recordings, proper 
environmental conditions (37°C/pH 7.4) were maintained by placing the culture dish in a 
microincubator. Cell trajectory was constructed by frame-by-frame analyses of the centroid 
positions (x, y) of cell-nuclei (assumed to be the representations of cell-bodies). The change in 
the direction of centroid movement between successive image frames (i-1, i, i+1) was calculated 
as ∆θ i= ∆θi, i+1 - ∆θi, i-1 (∆θi, i+1= cos-1(xi+1 – xi)/sqrt ((xi+1 – xi)2) + ((yi+1 – yi)2)) and from these 
values, the standard deviation of ∆θ was computed. For kymography, additional time-lapse 
movies were recorded for 10-20 min at a 5-sec time-interval. Kymographs marking the 
beginning to the end of protrusion were constructed based on 1-pixel wide (0.3 µm) lines drawn 
at multiple locations (3-4) across the protruding membrane. Membrane fluctuation <4 pixels (1.2 
µm) was disregraded for quantitative analyses. All images were acquired and analyzed using 
Metamorph and NIH ImageJ softwares, respectively. 
3.8 STATISTICS AND DATA REPRESENTATION 
All statistical tests were performed with ANOVA followed by Neuman-Keuls post-hoc test for 
multiple comparisons whenever applicable, and a p value less than 0.05 was considered to be 
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statistically significant. In most cases, experimental data were represented as box and whisker 
plots where dot represents the mean, middle lines of box indicates median, top of the box 
indicates 75th percentile, bottom of the box measures 25th percentile and the two whiskers 
indicate the 10th and 90th percentiles, respectively. 
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4.0  ROLE OF ENA/VASP IN HYPERMOTILE RESPONSE OF BREAST CANCER 
CELL 
Several lines of experimental evidence including motility defect of Pfn1,2-null Dictyostelium 
amebae [Haugwitz et al., 1994], Pfn1-mutant Drosophila [Verheyen et al., 1994], and Pfn1-
deficient human vascular endothelial cells [Ding et al., 2006] all point to a key role of Pfn1 in 
normal cell migration. Interestingly however, silencing Pfn1 expression leads to increased 
motility and invasiveness of breast cancer cell lines and conversely, overexpression of Pfn1 
dramatically suppresses the aggressive phenotype of breast cancer cells [Roy et al., 2004; Zou et 
al., 2007]. Taken together, these findings not only suggest that Pfn1’s role in cell migration is 
complex and contextual, but also make Pfn1 an interesting and highly relevant molecule for 
further investigation in pathological context. Specifically, how reduced Pfn1 expression might 
contribute to hyper-motile phenotype of breast cancer cells needs to be addressed. 
 
Specific Aim1: To determine whether VASP plays a role in the hypermotile response of 
breast cancer cells induced by loss of Profilin-1 expression. 
 
This chapter has been published in the following publication: 
Bae YH, Ding Z, Zou L, Wells A, Gertler FB and Roy P. (2009). Loss of profilin-1 expression 
enhances breast cancer cell motility by Ena/VASP proteins. J Cell Physiol 219: 354-364. 
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4.1 RESULTS 
4.1.1 Loss Pfn1 expression leads to faster random motility of MDA-231 breast cancer cells 
In our previous study, MDA-231, a highly invasive and metastatic breast cancer cell line, was 
found to be more motile in both wound-healing and transwell-based migration assays when Pfn1 
expression was silenced [Zou et al., 2007]. However, neither of these two migration assays 
allows for detailed investigation of cell motility and particularly in wound-healing assay, the 
speed of cell migration can also be influenced by cell-cell contact. Therefore, we examined the 
effect of Pfn1 knockdown on the motility of MDA-231 cells at the single-cell level to identify 
possible mechanisms underlying of the resulting increased motility of breast cancer cells. 
Specifically, we conducted time-lapse imaging of individual MDA-231 cells which were 
transiently transfected with either a pool of non-targeting control siRNAs or our previously 
validated siRNA targeting a single region of Pfn1-mRNA [Ding et al., 2006; Zou et al., 2007]. 
As an additional control, cells were also subjected to mock transfection. Immunoblotting of total 
cell lysate (TCL) extracted 72 h after siRNA transfection showed strong Pfn1 bands for either of 
the two control groups of cells, but virtually undetectable signal for Pfn1-siRNA treated MDA-
231 cells and HMEC (Fig. 4A). There was also no detectable change in Pfn1 expression between 
mock and control-siRNA transfection groups. These results demonstrate that we are able to 
achieve very close to 100% transfection efficiency and near complete suppression of Pfn1 
expression in MDA-231 cells and HMEC by siRNA treatment. Figure 4B shows the actual 
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trajectories of different groups of cells obtained from 2-h time-lapse recordings (data pooled 
from 3 experiments). From cell trajectory analyses, we found that the average speed of migration 
of Pfn1-deficient MDA-231 cells (~1.0 µm/min) was 1.9-fold higher than that of mock-
transfected (~0.52 µm/min) and control-siRNA treated cells (~0.53 µm/min); there was no 
significant difference in the average speed of cell migration between our mock and control-
siRNA treatment groups thus confirming the specificity of our findings (Fig. 4C). As an 
additional validation of our results, we repeated these time-lapse motility experiments with a set 
of pooled siRNAs that targets different regions of Pfn1-mRNA and we found close to 1.5-fold 
increase in the average speed of MDA-231 cell migration as a result of Pfn1 downregulation 
(data not shown). A 20% difference in the average speed of migration between single (~1.0 
µm/min) and pooled (~0.8 µm/min) Pfn1 siRNA-treated cells could be due to marginally better 
silencing of Pfn1 achieved with a single siRNA treatment (unpublished observation). 
Since breast cancer cells are of epithelial origin, we next analyzed the effect of Pfn1 
depletion on the random motility of normal HMEC which express Pfn1 at higher levels than 
breast cancer cell lines including MDA-231 cells [Janke et al., 2000; Zou et al., 2007] and also 
show better chemotactic migration in transwell assay in the absence of Pfn1 expression as 
demonstrated in our previous study [Zou et al., 2007]. Similar to our observation in MDA-231 
cells, depletion of Pfn1 in HMEC led to a 2.6-fold increase in the average speed of cell migration 
in time-lapse assay (Fig. 4C). Overall, these time-lapse motility observations for HMEC and 
MDA-231 cells are consistent with our previously reported wound-healing and transwell 
migration data [Zou et al., 2007]. 
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Figure 4: Silencing Pfn1 expression leads to faster motility of MDA-231 breast cancer cells 
and HMEC in time-lapse assay. A) Pfn1 immunoblot of MDA-231 cell and HMEC lysates 72 
h after siRNA transfection (the GAPDH blot serves as the loading control). B) Trajectories of 
individual MDA-231 cells of different experimental groups in time-lapse motility assay (data 
pooled from three independent experiments). C) A box and whisker plot representing the relative 
comparison of the average speed of migration between different treatment groups for MDA-231 
cells and HMEC. All results are normalized to the average value calculated for the control-
siRNA treated cells and “n” indicates the number of cells analyzed in each treatment group. The 
asterisk marks represent P < 0.05. 
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We also asked whether loss of Pfn1 expression affects the directionality of MDA-231 cell 
movement. From the sequence of images of individual cells for different experimental groups 
(shown in Fig. 5A), it became apparent that Pfn1-depleted cells change direction of migration 
less frequently than either of the two control groups of cells. To quantitatively represent this 
feature, we first scored the change in direction of centroid movement (∆θ) as a function of time 
from which we computed the standard deviation of ∆θ (a higher value indicates larger fluctuation 
in the directionality of movement). As summarized in the form of a box and whisker plot in 
Figure 5B, a somewhat smaller standard deviation of ∆θ of Pfn1-sRNA treated cells compared to 
either of the two control groups of cells suggests that Pfn1-depletion moderately enhances the 
directional persistence of motility of MDA-231 cells. 
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Figure 5: Silencing Pfn1expression enhances directional persistence of MDA-231 cell 
migration. A) Sequences of images from a set of representative time-lapse experiments of 
MDA-231 cells conducted for 2 h (arrow- direction of protrusion; scale- 10 µm). B) Relative 
comparison of the standard deviation of ∆θ (a measure of the change in the direction of centroid 
movement) during motility between different treatment groups of MDA-231 cells. The asterisk 
mark represents P < 0.05. 
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4.1.2 Effect of Pfn1 depletion on lamellipodial protrusion 
Lamellipodial protrusion initiates and defines the direction of cell movement. Among its 
different functions, Pfn1’s role has been best described in the context of membrane protrusion 
during cell migration. We therefore analyzed the leading edge movement of MDA-231 cells for 
different transfection conditions from kymographs of 1-pixel (0.3 µm) wide lines that were 
drawn normal to the leading edge and in the direction of protrusion. Figure 6A depicts a set of 
representative kymographs of the protrusion events of MDA-231 cells for different siRNA 
transfection conditions where leading edge traces (marked by the arrows) show cycles of typical 
lamellipodial protrusion and withdrawal (resemble saw-tooth waveforms as outlined by the 
boxes). Quantitative analyses of kymographs showed that the actual protrusion velocity (this is 
equal to the slope of the ascending portion of a saw-tooth waveform) of Pfn1-depleted MDA-231 
cells (=3.5 µm/min) is almost twofold less than that of control siRNA-treated cells (=7.2 
µm/min; Fig. 6B). However, since MDA-231 cells actually exhibit a gain in overall migration 
speed after Pfn1 depletion, further explanation was needed. During cell motility, a protruding 
lamellipodium often undergoes partial or complete retraction (also true for MDA-231 cells as 
shown in Fig. 6A) and therefore it is the net membrane protrusion that correlates with the 
efficacy of whole cell movement. When we analyzed the rate of net membrane protrusion of 
MDA-231 cells, we found that Pfn1-deficient cells have a significantly greater net protrusion 
velocity (=1.0 µm/min) compared to control siRNA treated cells (=0.6 µm/min; Fig. 6C). To 
explain this observation, we further examined the lamellipodial withdrawal events which showed 
that on an average, withdrawal of protrusion was more frequent in control (1/min) than in Pfn1-
depleted MDA-231 cells (0.5/min; Fig. 6D). Also, the magnitude of lamellipodial withdrawal 
significantly decreases when Pfn1 expression is suppressed (Fig. 6E). 
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Figure 6: Loss of Pfn1 expression leads to slower but more stable lamellipodial protrusion 
in MDA-231 cells. A) Kymographs representing lamellipodial dynamics of MDA-231 cells with 
or without Pfn1 depletion (leading edge traces are marked by the black arrows and the boxes 
outlining the saw-tooth waveforms represent typical lamellipodial protrusion and withdrawal 
events). B) A box and whisker plots comparing the actual protrusion velocities between control 
and Pfn1-siRNA treated MDA-231 cells (“n” represents the total number of protrusion events 
characterized by the saw-tooth waveforms). C) A box and whisker plot comparing the net 
protrusion velocity of MDA-231 cells with or without Pfn1 depletion (“n” indicates the number 
of kymographs analyzed). D-E)  Box and whisker plots comparing the frequency (part D) and 
average distance (part E) of lamellipodial withdrawal (i.e., the descending part of the saw-tooth 
waveforms) between control and Pfn1-siRNA treated MDA-231cells (“n” in parts D and E 
represent the total number of kymographs and withdrawal events, respectively). These data are 
based on analyses of 30 cells for each transfection condition pooled from three independent 
experiments. The asterisk marks represent P < 0.05. 
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4.1.3 Silencing Pfn1 expression enhances VASP localization at the leading edge 
Stable lamellipodial protrusion is one of the characteristic features of smooth and gliding type of 
cell movement. It has been recently shown that fish keratocytes (an extremely fast migrating 
epithelial cell type) migrate faster and in a smooth, gliding fashion when Ena/VASP family 
proteins are enriched at their leading edge [Lacayo et al., 2007]. Leading edge targeting of 
Ena/VASP has also been shown to result in faster membrane protrusion [Bear et al., 2002]. We 
therefore asked whether sub-cellular distribution of Ena/VASP in MDA-231 cells is altered by 
Pfn1-depletion. We focused on VASP because it is the most well-characterized member of the 
protein family. Since VASP is recruited to the leading edge in a protrusion-dependent manner, 
we performed costaining of VASP and phalloidin (to identify the leading edge of lamellipodia) 
of MDA-231 cells under different siRNA transfection conditions. Only those cells which formed 
prominent lamellipodia (identified from phalloidin-stained images) were selected for comparison 
of VASP distribution between the different treatment groups (Fig. 7A). VASP was localized at 
the leading edge of lamellipodia (arrowheads), focal adhesions (thick arrows) and occasionally, 
in dorsal ruffles (thin arrow). VASP signal at the very leading edge of lamellipodia was found to 
be conspicuously higher in Pfn1-depleted cells. Fluorescence intensity analyses of line scans 
across the leading edge showed that the average signal intensity of VASP at the very leading 
edge is almost fourfold higher in Pfn1-depleted cells than in control-siRNA treated cells (Fig. 
7B). Immunoblot analyses confirmed that silencing Pfn1 expression does not alter the overall 
expression level of VASP in MDA-231 cells (Fig. 7C). Since VASP binds to barbed ends of 
actin filaments [Bear et al., 2002] and previous studies have shown that cofilin, an F-actin 
severing protein, plays a key role in generating barbed ends of actin filaments in breast cancer 
cells [Chan et al., 2000], we also compared the expression level of cofilin between control and 
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Pfn1-depleted cells. Immunoblot data showed that cofilin expression in MDA-231 cells is not 
altered by Pfn1 depletion [Fig. 7C]. It is, however, noteworthy here that Pfn1 depletion results in 
a slight reduction in the total actin level in MDA-231 cells as demonstrated previously by our 
group [Zou et al., 2007]. Finally, to determine whether stronger VASP localization at the leading 
edge as a result of Pfn1 depletion is a reproducible feature in other cell types, we performed 
similar immunostaining experiments with HUVEC and normal HMEC. Interestingly, both cell 
lines also showed stronger VASP signal at the leading edge in the absence of Pfn1 expression 
therefore substantiating our findings (Fig. 7D). 
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Figure 7: Silencing Pfn1 expression enhances leading edge localization of VASP. A) VASP 
(red) and phalloidin (green) costaining of MDA-231 cells show stronger leading edge 
(arrowhead) localization of VASP in Pfn1-deficient cells (VASP localization at focal adhesion 
and ruffles are marked by thick and thin arrows, respectively; scale- 10 µm). Magnified forms of 
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the insets (outlined by the boxes) are displayed in the right most parts. B) A bar graph comparing 
the relative intensity of VASP staining at the lamellipodial edge between control and Pfn1-
depleted MDA-231 cells (a.u., arbitrary units; data summarized from two independent 
experiments and the asterisk mark denotes P < 0.05). C) Silencing Pfn1 does not alter the total 
expression level of VASP and cofilin in MDA-231 cells (GAPDH blot serves as the loading 
control). D) VASP immunostaining of HMEC and HUVEC show similar VASP enhancement at 
the leading edge as a result of Pfn1 depletion. Scale bars in all images represent 20 µm. 
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4.1.4 Ena/VASP is responsible for hypermotile phenotype of Pfn1-deficient MDA-231 
cells 
Inhibition of Ena/VASP function leads to cell-type specific changes in cell migration. Leading 
edge targeting of VASP correlates with faster migration of fish keratocytes [Lacayo et al., 2007], 
but in the case of fibroblasts, inhibition or deletion of Ena/VASP results in increased motility 
[Bear et al., 2000]. To determine whether lamellipodial targeting of VASP is responsible for 
creating hyper-motile phenotype of Pfn1-deficient MDA231 cells, we adopted a previously 
described strategy to inhibit Ena/VASP function by expressing Ena-VASP homology-1 (EVH1) 
binding motifs of ActA fused to a mitochondrial membrane anchor (EGFP-FPPPP-mito: referred 
to as “FP4-mito”). This particular construct effectively depletes all Ena/VASP proteins from 
their normal sites of function and sequesters them on mitochondria [Bear et al., 2000]. A 
similarly structured construct deficient in binding to Ena/VASP proteins (EGFP-APPPP-mito: 
referred to as “AP4-mito”) was used as a control. To demonstrate the efficacy of this construct in 
our cell system, we transfected Pfn1-siRNA treated MDA-231 cells with either AP4-mito or 
FP4-mito construct and then examined VASP localization by immunostaining (Fig. 8). As 
expected, VASP distribution was not affected by expression of the AP4-mito construct: Pfn1-
siRNA transfected cells bearing this construct still displayed strong VASP staining at their 
leading edges. However, cells expressing FP4-mito showed no VASP signal at the leading edge 
or in focal adhesions and instead exhibited the expected mitochondrial sequestration of VASP 
(specificity and efficacy of these two constructs were also confirmed for control-siRNA treated 
cells in a similar manner- data not shown). 
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Figure 8: Effects of expression of EGFP-FP4/AP4-mito on VASP localization in Pfn1-
deficient MDA-231 cells. GFP (green) images of Pfn1-siRNA treated cells show typical 
mitochondrial localization of AP4-mito and FP4-mito fusion proteins. Corresponding VASP 
immunostaining (red) images show that VASP’s localization to the leading edge and focal 
adhesion are affected only by FP4-mito expression. Merged images reveal complete 
colocalization of VASP with FP4-mito (appears yellow) but not with AP4-mito (scale- 20 μm). 
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Next, we performed time-lapse imaging of control and Pfn1-siRNA bearing MDA-231 
cells following transfection with either AP4-mito or FP4-mito construct and compared the 
migration speed of EGFP-negative (only carries siRNA) and EGFP-positive (expresses either 
AP4-mito or FP4-mito against siRNA background) cells. Figure 9A shows that for either of the 
siRNA treatment groups, there was no significant difference in the average speed of migration 
between EGFP-negative and the corresponding AP4-mito bearing cells. Expression of FP4-mito 
reduced the average speed of migration of control siRNA treated cells by a nominal 15% 
although this difference was not statistically significant. The average speed of AP4-mito 
expressing Pfn1-depleted cells was 50% higher compared to the corresponding control siRNA-
treated cells. The FP4-mito construct, however, reduced the speed of Pfn1-deficient cells by 
nearly 65%; the average speed of these cells was in fact 40% less than that of FP4-mito bearing 
control siRNA treated cells. Overall these data suggest that Ena/VASP compensates for the loss 
of Pfn1 and further augments the overall motility of MDA-231 cells when Pfn1 expression is 
silenced. 
Since Ena/VASP sequestration in Pfn1-deficient cells leads to a dramatic inhibition in 
motility, we speculated that lamellipodial protrusion of these cells might be compromised. To 
confirm this, we studied the leading edge dynamics of Pfn1-depleted MDA-231 cells with or 
without Ena/VASP sequestration. We found that the kymograph patterns of EGFP-negative and 
AP4-mito expressing cells were very similar; however FP4-mito expressing cells exhibited 
significant reduction in protrusion (as judged from a near-flat profile- Fig. 9B). Data analyses 
showed that Ena/VASP inhibition by FP4-mito resulted in nearly 70% reduction in the net 
protrusion velocity of Pfn1-defiicient MDA-231 cells (Fig. 9C), suggesting that lamellipodial 
targeting of Ena/VASP plays a major role in the protrusive activity of these cells. 
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Figure 9: Mitochondrial sequestration of Ena/VASP dramatically impairs the motility and 
lamellipodial protrusion of Pfn1-deficient MDA-231cells. A) A box-whisker plot summarizes 
the relative speed of control and Pfn1-siRNA treated cells with (FP4-mito) or without (either 
AP4-mito or EGFP-negative) mitochondrial sequestration of Ena/VASP (all data are normalized 
to AP-mito expressing control siRNA treated cells; “n” represents the number of cells analyzed 
for each group pooled from three independent 2-h long time-lapse experiments). The single and 
double asterisks represent P < 0.05 and P < 0.01, respectively. B) Representative kymographs 
showing leading edge traces (white arrows) of Pfn1-depleted MDA-231 cells with or without 
Ena/VASP inhibition. C) A box and whisker plot comparing the net protrusion velocities 
between the different treatment groups of Pfn1-deficient cells (data normalized to AP4-mito 
expressing cells and “n” indicates the number of cells in each group pooled from three-
independent experiments; *P < 0.05). 
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Ena/VASP proteins bind to the barbed ends of actin filaments and support actin 
polymerization in the presence of actin filament capping proteins [Barzik et al., 2005; Pasic et 
al., 2008]. This has been proposed to be the mechanism underlying Ena/VASP-driven membrane 
protrusion. Leading edge localization of VASP in fibroblasts and keratocytes requires free 
barbed ends of growing actin filaments [Bear et al., 2002; Lacayo et al., 2007]. In our case, when 
we treated Pfn1-depleted MDA-231 cells with 100 nM cytochalasin D (CD; under these 
conditions CD works mainly as a pharmacological barbed-end capper without causing significant 
depolymerization of actin filaments [Bear et al., 2002]) for 30 min, VASP became completely 
delocalized from the leading edge while treatment with carrier DMSO had not effect at all (Fig. 
10). Phalloidin counterstaining confirmed that 100 nM CD treatment did not cause any major 
depolymerization of actin filaments; also the characteristic fan-shaped lamellipodial structure 
(arrow) was seen to be preserved. Antagonistic action of CD on lamellipodial targeting of VASP 
is consistent with VASP’s binding to the barbed ends of actin filaments as expected. 
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Figure 10: Lamellipodial targeting of VASP in Pfn1-deficient MDA-231 cells is sensitive to 
low dose of cytochalasin-D (CD) treatment. VASP immunostaining images of Pfn1-deficient 
cells show that VASP is completely delocalized from the leading edge (arrow) when exposed to 
100 nM CD for 30 minutes while diluent DMSO treatment has no effect. F-actin counterstaining 
by phalloidin show that 100 nM CD does not lead to any major depolymerization of actin 
filaments or disruption of lamellipodia (scale - 20 μm). 
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4.2 DISCUSSION 
Gain-of-motility of certain types of adenocarcinoma cells induced by loss of Pfn1 expression has 
been previously reported by us and others [Wu et al., 2006; Zou et al., 2007]; but, the 
mechanisms underlying this effect have not been delineated yet. This has been challenging 
particularly since Pfn1 has been traditionally viewed as a molecule required for cell migration. 
This study was the first attempt to identify a possible mechanism of how reduced Pfn1 
expression could actually promote migration of breast cancer cells. 
Our time-lapse data revealed that silencing Pfn1 expression leads to faster motility of 
both MDA-231 breast cancer cells and normal HMEC. This is in contrast to the behavior of 
HUVEC which exhibit significantly reduced motility after Pfn1 depletion as shown by our group 
in a previous study [Ding et al., 2006]. To better understand the physical basis for cell-specific 
difference in the overall motility response resulting from Pfn1 depletion, we studied the 
lamellipodial dynamics of HUVEC [Bae et al., 2009] and MDA-231 cells and found that in both 
cell types, the actual protrusion velocity is reduced when Pfn1 expression is suppressed. This is 
the first direct demonstration of the effect of Pfn1 depletion on the actual protrusion velocity of 
cells, and is consistent with previously shown slower intracellular propulsion of bacterial 
pathogens in the absence of Pfn1 [Loisel et al., 1999; Mimuro et al., 2000]. Interestingly, Pfn1-
deficient MDA-231 cells showed less withdrawal of protrusion, both in terms of its frequency 
and magnitude, compared to control cells which eventually resulted in a more effective net 
protrusion and an overall increase in motility. 
We found a striking enrichment of VASP at the very leading edge of MDA-231 cells as a 
consequence of Pfn1 depletion, and this finding was also reproducible in both HMEC and 
HUVEC. We further showed that specifically Pfn1-deficient but not control MDA-231 cells 
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become severely impaired in motility when Ena/VASP function is inhibited by mitochondrial 
sequestration. These data imply that (1) Pfn1 by itself still acts as a pro-migratory molecule in 
MDA-231 cells as literature has demonstrated in other cell types (Haugwitz et al., 1994; Ding et 
al., 2006), and (2) it is the enhanced Ena/VASP localization at the leading edge which rescues 
and further augments the overall motility of MDA-231 cells when Pfn1 expression is silenced. 
Although we have only studied VASP localization in this study, the other two Ena/VASP 
proteins, Mena and EVL have overlapping functions and localization with VASP. Therefore, it is 
likely that Mena also contributes to the hypermotile phenotype of Pfn1-deficient cells as it is 
expressed robustly in MDA-231 cells (unpublished observation in Dr. Gertler laboratory). The 
mitochondrial sequestering construct used in this study is effective against all three members of 
Ena/VASP protein family; whether there are any differences in the contributions of Mena or 
VASP to the phenotype of Pfn1-deficient cells remains to be determined. 
Ena/VASP proteins have a well-established role in promoting membrane protrusion 
[Rottner et al., 1999]. Previous studies showed that Ena/VASP increases the speed of 
intracellular actin-driven propulsion of Listeria monocytogenes [Laurent et al., 1999; Geese et 
al., 2002] and leading edge targeting of VASP correlates with faster protrusion in cells [Bear et 
al., 2002; Lacayo et al., 2007]. Mitochondrial sequestration of Ena/VASP leading to reduced 
membrane protrusion in Pfn1-deficient MDA-231 cells is consistent with those findings. 
Ena/VASP can bind Pfn1-actin complexes in an orientation favorable for transfer of monomer to 
growing barbed ends. Ena/VASP is known to facilitate actin polymerization by antagonizing the 
action of F-actin capping proteins [Bear et al., 2002]; the anti-capping activity does not require 
Pfn, but is enhanced by the presence of Pfn [Barzik et al., 2005]. In the present case, leading 
edge targeting of VASP facilitates lamellipodial protrusion in a near absence of Pfn1 expression. 
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In a previous study, we failed to detect Pfn2 expression in MDA-231 cells at least by 
immunoblotting [Zou et al., 2007]. Although it is possible that very low levels of residual Pfn1 
or Pfn2 enhance VASP-dependent actin polymerization, the contribution should be minimal. 
Therefore, it is likely that VASP drives membrane protrusion via Pfn-independent anti-capping 
action. 
The effect of Ena/VASP perturbation on the overall cell motility is cell-type dependent. 
This apparent discrepancy between different model systems is not completely surprising. 
Although the actual protrusion velocity increases when VASP is targeted to the leading edge, the 
overall persistence of protrusion and the net cell movement decrease in the case of slow-moving 
fibroblasts. This is because VASP-mediated protrusions in fibroblasts tend to be unstable and are 
prone to withdrawal [Bear et al., 2002]. The lamellipodial dynamics of rapidly migrating cell 
types such as fish epithelial keratocytes show much less oscillatory behavior when compared to 
fibroblasts, and therefore, the overall motility response of these cells to leading edge targeting of 
VASP can be quite different. Interestingly, our data showed that protrusions generated by Pfn1-
deficient MDA-231 cells are less susceptible to withdrawal therefore implying enhanced stability 
of these protrusions, and this is likely to be a result of better protrusion-adhesion coupling.  
Although the underlying mechanism is not clear, one simple explanation could be that since 
Pfn1-silenced cells protrude slower, these protrusions may have a better chance of engagement to 
the underlying substrate via adhesion receptors. 
A key question remaining to be investigated in detail is how absence of Pfn1 expression 
leads to VASP enrichment at the leading edge. One possibility is that both control and Pfn1-
depleted cells have comparable efficiency of targeting VASP to the membrane during protrusion. 
Since Pfn1-depleted cells show evidence of less withdrawal of protrusion, it is possible that 
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VASP-rich protruding membrane is better sustained and represented in fixed-cell preparations, as 
in immunostaining experiments. However, a comparable efficiency of targeting VASP to the 
leading edge is unlikely to result in a fourfold difference in membrane staining of VASP between 
control and Pfn1-depleted MDA-231 cells. An alternative explanation that we favor is that 
silencing Pfn1 expression actually increases the membrane targeting efficiency of VASP. Since a 
deletion mutant of VASP lacking its polyproline domain (a region that binds to Pfn1) targets 
normally to the leading edge [Loureiro et al., 2002], Pfn1 is unlikely to have a direct effect on 
Ena/VASP targeting to the leading edge. Therefore, we think loss of Pfn1 expression enhances 
leading edge targeting of VASP through an indirect mechanism, possibly involving Lpd as to be 
examined in specific Aim 2.  
In conclusion, we have now identified a possible mechanism of how loss of expression of 
a pro-migratory molecule like Pfn1 can result in increased migration of breast cancer cells 
through enhanced lamellipodial targeting of Ena/VASP proteins. We will need to determine the 
generalizability of our findings by expanding our studies to other breast cancer cell lines and 
other types of adenocarcinoma that have reduced Pfn1 expression compared to their normal 
counterparts. 
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5.0  PHOSPHOINOSITIDE-INTERACTION MEDIATED INHIBITORY ACTION OF 
PROFILIN-1 ON BREAST CANCER CELL MIGRATION 
A key cellular function downstream of membrane D3-PPI signaling events is the regulation of 
actin cytoskeletal dynamics which is critical for overall cell motility [Blume-Jensen et al., 2001]. 
During tumor progression, this cellular function of D3-PPI becomes dysregulated. Among the 
D3-PPI groups, PIP3 has been mostly studied in Dictyostelium and neutrophil model systems in 
the context of directional sensing and motility during chemotaxis. However, a major gap in the 
literature is the lack of understanding of specific signaling functions of membrane PI(3,4)P2 
(another byproduct of PI3K signaling) in cancer cell motility. Recently, lamellipodin (Lpd; an 
adaptor protein which binds to and recruits Ena/VASP family protein to the leading edge), has 
been identified and noted that it binds to pH domain of PI(3,4)P2 with high selectivity [Krause et 
al., 2004]. Ena/VASP localization at the leading edge associates with faster and in a smooth, 
gliding fashion of migration in fish keratocytes [Lacayo et al., 2007]. One of the possible links 
between D3-PPI signaling and regulation of actin dynamics at the leading edge of migrating cells 
is Lpd-mediated VASP recruitment and this needs to be investigated. 
 
Specific Aim2: To examine whether Pfn1 inhibits breast cancer cell motility by 
regulating D3-phosphoinositide availability for lamellipodin targeting to the membrane. 
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Some of the contents in this chapter have been or will be published in the following 
publications: 
Bae YH, Ding Z, Zou L, Wells A, Gertler F, Roy P. (2009). Loss of profilin-1 expression 
enhances breast cancer cell motility by Ena/VASP proteins. J Cell Physiol 219: 354-364. 
 
Bae YH, Ding Z, Das T, Wells A, Gertler FB, Roy P. Membrane PI(3,4)P2 availability, regulated 
by profilin-1, impacts breast cancer cell motility secondary to lamellipodin binding. 
[Under Review: 02/2010] 
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5.1 RESULTS 
5.1.1 Pfn1 inhibits breast cancer cell motility by negatively regulating VASP/Lpd 
targeting to the leading edge 
Lpd, a protein that contains a PH (pleckstrin-homology) domain with affinity for PI(3,4)P2, has 
been identified as one of the potential linkers for targeting Ena/VASP close to the plasma 
membrane at the leading edge and at least for fibroblasts, Lpd has been shown to play an 
important role in membrane protrusion [Krause et al., 2004]. Lpd staining of Pfn1-siRNA treated 
MDA-231 cells showed its localization at the lamellipodial tip (arrows) and ruffles (arrowheads- 
Fig. 11A). There was also a very strong colocalization of Lpd and VASP at the leading edge 
(Fig. 11A). As shown previously in fibroblasts [Krause et al., 2004], Lpd targeting to the leading 
edge in our cells is not VASP-dependent since expressing FP4-mito that sequesters Ena/VASP to 
mitochondria still preserves strong leading edge staining of Lpd (Fig. 11B). To determine 
whether Lpd plays a role in VASP targeting to the leading edge in Pfn1-depleted MDA-231 cells 
we transfected MDA-231 cells with Pfn1-siRNA either alone or together with Lpd-siRNA. We 
found that co-suppression of Lpd and Pfn1 expression in MDA-231 cells by dual siRNA 
treatment (Fig. 11C) results in markedly reduced VASP distribution at the leading edge (Fig. 
11D) thus confirming critical requirement of Lpd for lamellipodial targeting of VASP in our cell 
line.  
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Figure 11: VASP is colocalized with Lpd at the leading edge in Pfn1-deficient cells. A) 
Immunostaining shows complete colocalization of VASP (red) and Lpd(green) at the leading 
edge (arrows) in Pfn1 depleted MDA-231 cells (appears yellow in the merged image). B) Pfn1-
silenced MDA-231 cells expressing FP4-mito (green) maintain strong leading edge targeting of 
Lpd (red). The merged image in the right most part shows no overlapping of these two 
fluorescence signals. C) Immunoblot data showing dual suppression of Lpd and Pfn1 in MDA-
231 cells by siRNA cotransfection (GAPDH blot - loading control). D) VASP and Lpd 
costaining of MDA-231 cells transfected with Pfn1 siRNA either alone or together with Lpd 
siRNA. 
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Next, we observed that silencing Pfn1 leads to a significant 4-fold increase in Lpd 
distribution at the leading edge in MDA-231 cells, and conversely, MDA-231 cells stably 
overexpressing GFP-Pfn1 about two-fold [Smith et al., 2010] present 25% less Lpd content at the 
lamellipodial tip when compared to the corresponding control GFP expressers (Fig. 12A and Fig. 
12B). Note that loss of Pfn1 expression has no effect on the overall expression of Lpd in MDA-
231 cells (Fig. 12C). We additionally found that Lpd enrichment at the leading edge induced by 
silencing of Pfn1 is reproducible in at least two other cell types including normal HMEC and 
HUVEC (human umbilical vein endothelial) (Fig. 12D). Interestingly, while the HMEC are 
similarly hypermotile upon Pfn1 depletion, [Bae et al, 2009], the HUVEC become hypomotile 
[Ding et al., 2006]. Thus, Pfn1-dependent regulation of Lpd localization appears be a generalized 
phenomenon. 
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Figure 12: Pfn1 is a negative regulator of lamellipodial targeting of Lpd. A) Lpd 
immunostaining data showing the effects of silencing and stable overexpression of Pfn1 in 
parental MDA-231 cells on Lpd localization at the leading edge (arrows). B) A bar graph 
comparing the relative intensity of Lpd staining at the lamellipodial edge in MDA-231 cells after 
silencing (grey bars) and overexpression (black bars) of Pfn1 ( ‘n’ - number of cells analyzed; **: 
p<0.01; *: p<0.05). C) Immunoblot showing comparable Lpd level between control and Pfn1-
siRNA treated MDA-231 cells (GAPDH blot - loading control). D) Lpd immunostaining 
showing Lpd enrichment at the lamellipodial tip in response to Pfn1-siRNA treatment in both 
normal HMEC and HUVEC (arrow) (scale bar - 20μm). 
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We next asked whether Lpd plays a role in the hypermotile response of Pfn1-depleted 
MDA-231 cells. Previously, Lpd knockdown was shown to cause impaired lamellipodia 
formation and reduce velocity of protrusion in fibroblasts [Krause et al, 2004]. When we 
compared morphology of control and Lpd-siRNA treated MDA-231 cells on tissue-culture 
substrate without any ECM coating, we also found that limiting Lpd expression somewhat 
decreases the overall flare of lamellipodial protrusion (as judged by the narrowing of lamellipod 
in Lpd knockdown cells) (Fig. 13A). Phenotypic change induced by Lpd suppression appears to 
be more prominent when Pfn1 expression is simultaneously downregulated as many cells in this 
group even fail to form proper lamellipodia (Fig. 13A). Interestingly, when the same groups of 
cells are seeded on collagen-coated substrate (mimics the substrate condition for motility 
experiments), Lpd knockdown alone does not appear to have any significant morphological 
consequence in MDA-231 cells as judged by normal appearing lamellipodia in both control and 
Lpd-siRNA treated cells, and only a small difference (~8%) in the fraction of cells with 
lamellipodia formation between the two groups (Fig. 13B). In the same experimental setting, 
lamellipodia formation in Pfn1-deficient cells, however, appears to be still significantly inhibited 
by Lpd knockdown as judged by a significant 31% lower fraction of cells forming lamellipodia 
(Fig. 13B). Consistent with these phenotypic distinctions, time-lapse migration assay showed 
that limiting Lpd expression does not have any significant effect on the motility of parental 
MDA-231 cells, but drastically reduces the average speed of Pfn1-deficient cells (Fig. 13C). 
These data demonstrate that hypermotile response of MDA-231 cells induced by Pfn1-
downregulation is Lpd-mediated. Differential sensitivity between control vs Pfn1 knockdown 
cells to Lpd depletion could be due to possible compensatory action by other Pfn1-binding Lpd-
homolog proteins as elaborated in the discussion. Given that lamellipodia formation/protrusion is 
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driven largely by actin polymerization, we next examined the effect of Lpd depletion on actin 
cytsokeletal structure in Pfn1-defiicient cells by phalloidin staining. We found that Lpd 
knockdown results in significantly reduced F-actin content at the leading edge (as judged by the 
intensity of phalloidin staining – Fig. 13D) and a concomitant ~3 fold decrease in the net 
protrusion velocity of Pfn1-deficient cells (Fig. 13E). Note that similar to MDA-231 cells, the 
average speed of Pfn1-deficient HMEC is also reduced by 40% when Lpd expression is 
suppressed (Fig. 13F). 
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Figure 13: Lpd plays a key role in the hypermotile response of Pfn1-deficient MDA-231 
cells. A) Phase-contrast micrographs of MDA-231 cells plated on tissue culture substrate without 
ECM coating following transfection of various siRNAs indicated in the figure (scale bar - 50μm). 
B) Phase contrast micrographs of MDA-231 cells plated on collagen-coated tissue-culture 
substrate show defect in lamellipodia formation (marked by asterisks) only in cells with co-
suppression of Lpd and Pfn1 expression (mean ± sd values for % of cells with lamellipodia 
formation for the various siRNA-treated groups are indicated below; data summarized from 2-3 
independent expts with >125 cells analyzed in each group). Scale bar - 50μm. C) A box and 
whisker plot comparing the average speed of migration of control and Pfn1-siRNA treated 
MDA-231 cells with or without limiting Lpd expression. D) Phalloidin staining reveals marked 
reduction in F-actin content at the leading edge (arrows) in Pfn1-depleted cells when Lpd 
expression is downregulated (scale bar - 20μm). E) A box and whisker plot comparing the net 
protrusion rate of Pfn1-depleted MDA-231 cells with or without Lpd suppression. F) A box and 
whisker plot comparing the average migration speed of Pfn1-depleted HMEC with or without 
Lpd suppression (n’ indicates the number of cells analyzed in each treatment group and ** 
denotes p<0.01). 
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5.1.2 Pfn1 exerts its inhibitory action on breast cancer cell motility predominantly 
through its phosphoinositide interaction 
In order to obtain insight on how reduced Pfn1 level increases breast cancer cell motility, we first 
asked which among the three major ligand interactions of Pfn1 (i.e actin, polyproline or 
phosphoinositide) predominantly inhibits breast cancer cell migration. To address this question, 
we stably expressed either GFP-Pfn1 (fully functional form of Pfn1) or various previously 
characterized ligand-binding deficient mutants of Pfn1 in MDA-231 (a highly aggressive breast 
cancer cell line which expresses significantly lower Pfn1 compared to normal HMEC and 
display dramatically enhanced motility upon Pfn1 depletion [Zou et al., 2007; Bae et al., 2009]) 
cells. Note that fusing GFP to the N-terminus of Pfn1 as done in our case preserves the 
biochemical functions and cellular localization of the fusion protein similar to that of 
endogenous Pfn1 [Wittenmayer et al., 2000]. The various GFP-tagged Pfn1 mutants we 
expressed are: H119E-Pfn1 as actin-binding mutant (it has a ~30 fold reduction in actin-binding 
compared to wild-type Pfn1 but retains normal polyproline binding), H133S-Pfn1 as polyproline-
binding  mutant (it has normal actin and PI(4,5)P2-binding but 50-fold less polyproline-binding 
compared to wild-type) and R88L-Pfn1 as PPI-binding mutant (it has normal polyproline binding 
but is substantially defective in PI(4,5)P2 binding (less than 30% of the wild-type value)) [Zou et 
al., 2007; Suetsugu et al., 1998; Sohn et al., 1995; Wittenmayer et al., 2004; Ezezika et al., 2009; 
Lu et al., 2001; Richer et al., 2008]. Note that like all PPI-binding deficient mutants discovered 
to date, R88L-Pfn1 mutant also has ~2-3-fold deficiency in actin-binding because of partial 
structural overlap between PPI and actin binding sites of Pfn1 [Sohn et al., 1995; Wittenmayer et 
al., 2004]. We engineered all of these Pfn1 constructs to be resistant to Pfn1-siRNA treatment by 
introducing additional silent mutations in the siRNA-targeting region; this strategy enabled us to 
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express these various constructs in MDA-231 cells in the background of strongly suppressed 
endogenous Pfn1 expression achieved via Pfn1-siRNA treatment. As a control, we used our 
previously generated stable GFP expresser of MDA-231 cells [Zou et al., 2007] which were 
transfected with either non-targeting control or Pfn1-siRNA. The immunoblots in the inset of 
Figure 14A demonstrate that i) we are able to express various GFP-Pfn1 constructs in the 
background of a close to 100% suppression of endogenous Pfn1 expression, and ii) the relative 
expression of these Pfn1 constructs are similar between the different sublines of MDA-231 cells. 
We estimated the level of exogenous Pfn1 to be approximately 70-80% of that of endogenous 
Pfn1 (Fig. 14B). Sub-cellular fractionation analyses showed that GFP-Pfn1 is more abundantly 
localized in cytosol than at the membrane, as in a previously report in other cell types [Hartwig 
et al., 1989] (Fig. 14C). Note that similar to endogenous Pfn1, GFP-Pfn1 is also localized in 
nucleus to a certain extent (nuclear localization is strongest for H119E-Pfn1 mutant) which was 
not analyzed in the fractionation experiment. As expected from its reduced binding to PPI, 
membrane content of R88L-Pfn1 mutant was found to be significantly less compared to the other 
three variants of Pfn1 (Fig. 14D).  
When we compared the relative speed of migration of these various cell lines by time-
lapse imaging, we found that that the average speed of control GFP expressers increases by ~2 
fold when Pfn1 expression is silenced (this is consistent with our previous observation on 
parental MDA-231 cells [Bae et al., 2009]), and the hypermotile phenotype of Pfn1-deficient 
cells can be completely rescued by GFP-Pfn1. Among the various Pfn1 mutants, H119E-Pfn1 
and H133S-Pfn1 rescue the hypermotile response of Pfn1-silenced cells by nearly 70% and 85%, 
respectively; but R88L-Pfn1 mutant fails to rescue the hypermotile phenotype (in fact, there was 
no significant difference in the average speed between R88L-Pfn1 re-expressers and control GFP 
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cells in suppressed endogenous Pfn1 background) (Fig. 14E). Even though R88L substitution 
decreases actin-binding of Pfn1 by 2-3 fold in addition to causing a major defect in its PPI 
binding, given that expression of H119E-Pfn1 (a much more potent actin-binding mutant which 
has a ~30-fold reduction in actin-binding compared to wild-type Pfn1) is able to reduce the speed 
of Pfn1-deficient cells by 70%, our data strongly suggests that the hypermotile response of the 
R88L mutant is not related to loss of Pfn1’s interaction with actin. Also, since the average speed 
of GFP-Pfn1-H119E expressers is somewhat higher than that of GFP-Pfn1 expressers, this rules 
out an alternative explanation of our motility data based on mutual exclusion of actin and PPI 
interaction of Pfn1 i.e. “R88L-Pfn1 being less sequestered at the membrane enhances cell 
motility through more frequent association with actin”. Therefore, hypermotile response of 
R88L-Pfn1 mutant is attributed to loss of PPI interaction of Pfn1. 
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Figure 14: Pfn1 inhibits MDA-231 breast cancer motility predominantly through its PPI 
interaction. A) Pfn1 and GFP immunnoblots show the endogenous and exogenous Pfn1 contents 
for various stable sublines of MDA-231 cells under different siRNA treated conditions (Pfn1 and 
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of GFP expressers that are transfected with control siRNA serves as a standard for comparison; 
GAPDH blot - loading control). B) Pfn1 immunoblot of GFP-Pfn1 expressers shows relative 
levels of endogenous and exogenous Pfn1.C-D) GFP-immunoblot of equal amounts of protein 
from cytosolic (CF) and membrane (MF) fractions of GFP-Pfn1 rescue expressers, shows 
relative abundance of GFP-Pfn1 in cytosol and membrane (panel C). GFP immunoblots of CF 
and MF show the relative cytosolic and membrane contents of GFP-Pfn1 and its various mutants 
in the respective sublines (panel D - note that the exposure time for MF blot shown in panel D is 
much higher than the corresponding CF blot to reveal the weak MF band for R88L-Pfn1). EGFR 
and GAPDH blots serve as the markers for MF and CF samples, respectively. E) A box and 
whisker plot summarizing the effect of abolishing various ligand interactions of Pfn1 on the 
average speed of migration of MDA-231 cells. ‘‘N’ indicates the number of cells analyzed in 
each group pooled at least 3 independent experiments analyzed (**: p<0.01). 
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We previously showed that Pfn1 depletion results in slower but more stable (less prone to 
withdrawal) membrane protrusion thereby increasing the net protrusion velocity of parental 
MDA-231 cells [Bae et al., 2009]. Importantly, the cells analyzed in each of these six groups 
form normal appearing lamellipodia in motility experiments (Fig 15A); however, kymography 
analyses of membrane protrusion showed that the average net protrusion velocity of R88L-Pfn1 
mutant cells (=1.15 μm/min) is significantly higher than any of the other rescue cell lines and 
very similar to the value obtained for Pfn1-depleted cells (=1 μm/min) (Fig. 15B-C). Overall, our 
findings indicate that Pfn1 inhibits MDA-231 cell migration predominantly through its PPI 
interaction. Note that we did not find any significant difference in either actin expression or the 
overall cellular F-actin level between GFP-Pfn1 (full rescue) and GFP-Pfn1-R88L rescue 
expressers (Fig 16); therefore, a striking difference in the protrusion kinetics between the two 
cell lines suggests that F-actin dynamics and/or protrusion/adhesion coupling at the leading edge 
are likely to altered by the PPI mutation of Pfn1. 
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Figure 15: Protrusion dynamics of various sublines of MDA-231 cells. A) Phase-contrast 
micrographs of migrating cells show normal appearing lamellipodia (arrows) formed by the 
various experimental groups of MDA-231 cells. B-C) A set of representative kymographs of 
protruding membrane (panel B) and a box and whisker plot comparing the net protrusion rate 
(panel C) between the different experimental groups of cells measured from kymography assay 
(‘‘N’ indicates the number of cells analyzed in each group pooled at least 3 independent 
experiments analyzed (**: p<0.01). 
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Figure 16: A) A comparison of total cellular F-actin content between GFP-Pfn1 and GFP-Pfn1-
R88L rescue sublines of MDA-231 cells as measured by either fluorescence assay (data 
summarized from 3 independent experiments) or immunoblot-based detection of actin in the 
triton-insoluble fraction of cell lysate (inset of panel A). B) Relative actin expression between 
the two cell lines. Vimentin blots serve as the loading controls. 
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5.1.3 Pfn1 inhibits breast cancer cell motility by negatively regulating Lpd targeting to 
the leading edge through its phosphoinositide interaction 
We previously demonstrated that lowering Pfn1 expression in normal HMEC and MDA-231 
cells enhances lamellipodial targeting but not the total expression level of VASP (a protein 
known to localize at focal adhesion, distal rim of lamellipodia, filopodia and actin stress-fibers 
[Rottner et al., 1999]) and that hypermotile response of Pfn1-deficient MDA-231 cells is 
Ena/VASP-dependent [Bae et al., 2009]. Membrane targeting of Ena/VASP proteins also 
positively correlates with protrusion velocity and overall speed of migration of fish scale 
keratocytes, another rapidly migrating cell type [Lacayo et al., 2007]. Given our present data 
with MDA-231 cells showing similar overall speed and net protrusion velocity between R88L-
Pfn1 rescue expressers and Pfn1 knockdown cells, we asked whether PPI-interaction of Pfn1 
plays any role in regulating VASP targeting to the leading edge. Indeed, immunostaining of our 
various rescue cell lines showed that VASP-rich lamellipodial rim, a feature of Pfn1-depleted 
cells, is mimicked predominantly in R88L-Pfn1 expressers (Fig. 17A) thus demonstrating that 
PPI interaction of Pfn1 inhibits targeting of VASP to the leading edge in MDA-231 cells. Similar 
to our finding related to VASP, we found that among the various rescue sublines of MDA-231 
cells, only R88L-Pfn1 expressers display a very strong Lpd-staining at the lamellipodial tip 
similar to what is seen in Pfn1-knockdown cells (Fig. 17B). Note that the same R88L-Pfn1 
expressers, when treated with control-siRNA (mimics a moderate overexpression setting), 
neither exhibit Lpd-rich lamellipodial tip (Fig. 17C) nor produce a hypermotile phenotype when 
compared to control GFP expressers (Fig. 17D). Similarly, in a transient-transfection based assay, 
the difference in the average speed between GFP and GFP-Pfn1-R88L overexpresser was found 
to be only 10% (not statistically significant) which further confirmed the results from stable 
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expressers in control siRNA-based setting. Since endogenous Pfn1, when present in R88L-Pfn1 
expressers, should still be able to interact with the membrane, these overexpression-based results 
further establish that the phenotypes exhibited by R88L-Pfn1 mutant in a rescue situation (i.e in 
the absence of endogenous Pfn1 expression) are specifically due to the loss of PPI interaction of 
Pfn1 and not secondary to other changes induced by the mutant. In summary, our findings thus 
far demonstrate that Pfn1 negatively regulates membrane targeting of Lpd and VASP at the 
leading edge through its PPI interaction. 
Since R88L-Pfn1 rescue expressers phenocopy Pfn1-knockdown cells in terms of 
comparable hypermotile response, net protrusion velocity, formation of Lpd/VASP-rich 
lamellipodial rim, we next asked whether VASP and Lpd contribute to the hypermotile response 
of this rescue cell line. To assess the contribution of VASP, we expressed mCherry-tagged FP4-
mito, a construct that sequesters all members of Ena/VASP proteins to the mitochondria thereby 
inhibiting their function (as a control, cells were transfected with mCherry-tagged AP4-mito, a 
similar structured construct that also targets to mitochondria but fails to bind to Ena/VASP 
proteins). Figure 17E shows Ena/VASP inhibition by mCherry-FP4-mito results in a ~ 3.2-fold 
reduction in the average speed of migration of R88L-Pfn1 expressers. This is specific to 
Ena/VASP inhibition since expression of mCherry-AP4-mito (control construct) did not show 
any significant change in motility when compared to untransfected (mCherry-negative) cells. 
Likewise, motility of R88L-Pfn1 mutant cells also showed strong dependence on Lpd 
availability since limiting Lpd expression by siRNA treatment led to a 2-fold decrease in cell 
speed (Fig. 17F - the immunoblot in the inset confirms Lpd suppression by siRNA treatment). A 
stronger inhibitory effect of VASP inhibition (~3.2 fold) compared to Lpd depletion (~2 fold) on 
motility of R88LPfn1 mutant cells was not surprising given that we failed to achieve a complete 
 64 
knockdown of Lpd expression by siRNA treatment whereas we have seen that FP4-mito 
construct is highly effective in sequestering all of the detectable cellular pool of VASP to the 
mitochondria in MDA-231 [Bae et al., 2009]. Given Lpd’s requirement for VASP recruitment to 
the leading edge, our overall data indicate that PPI interaction of Pfn1 confers the major 
inhibitory effect of Pfn1 on breast cancer cell motility secondary to the availability of Lpd and in 
turn VASP at the leading edge. 
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Figure 17: Pfn1 limits VASP and Lpd distribution at the leading edge through its PPI 
interaction. A) Immunostaining show that only R88L-Pfn1 expressers show strong VASP 
localization at the leading edge (arrow) similar to Pfn1-depleted cells (arrowheads shows the 
characteristic focal adhesion localization of VASP). B) Lpd staining of various rescue expressers 
of MDA-231 cells shows strongest Lpd-staining at the lamellipodial tip in R88L-Pfn1 rescue 
subline. Magnified forms of the insets (outlined by the boxes) are displayed above. C) Lpd 
immunostaining of GFP-Pfn1-R88L expressers of MDA-231 cells following control siRNA 
transfection. D) A bar graph summarizing the average speed of migration of GFP and GFP-Pfn1-
R88L expressers following control siRNA transfection. ‘N’ indicates the number of cells 
analyzed for each group of cells pooled from 2 independent experiments. E) A box and whisker 
plot demonstrates that Ena/VASP sequestration by mCherry-FP4-mito dramatically inhibits 
motility of R88L-Pfn1 mutant expressers. Untransfected or m-Cherry-AP4 transfected cells serve 
as the two control groups in Ena/VASP sequestration experiments. “N” indicates the number of 
cells analyzed for each experimental group pooled from at least 3 independent experiments (**: 
p<0.01). F) A box and whisker plot comparing the average speed of migration of R88L-Pfn1 
expressers with or without Lpd suppression (the immunoblot in the inset shows strong 
suppression of Lpd expression; GAPDH blot - loading control). For all experiments, ‘‘N’ 
indicates the number of cells analyzed in each group pooled from at least 3 independent 
experiments (**: p<0.01). The scale bar in all images represents 20 µm. 
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5.1.4 Loss of Pfn1 expression enhances PI(3,4)P2 presentation at the leading edge 
In vitro studies showed that PH domain of Lpd binds specifically to PI(3,4)P2 (this does not bind 
to any other 3’-phosphorylated-PPI [D3-PPI] such as PI3P or PI(3,4,5)P3) [Krause et al., 2004]. 
A recent study further demonstrates that enteropathogenic bacteria generates PI(3,4)P2-rich 
platform at the host-cell membrane to recruit Lpd [Smith et al., 2010] thus suggesting that Lpd 
docks to plasma membrane via its binding primarily to PI(3,4)P2. Activation of various receptor 
tyrosine kinases such as EGFR (EGF-receptor) and PDGFR (PDGF-receptor) stimulate PI3-
kinase [PI3K] activity and generate PI(3,4,5)P3, which when dephosphorylated by 5’-
phosphatases (such as SHIP2) lead to the production of PI(3,4)P2. To initially confirm the role of 
D3-PPI (such as PI(3,4)P2) in VASP and Lpd targeting to leading edge in our case, we subjected 
Pfn1-deficient MDA-231 cells (either without or with R88L-Pfn1 rescue) to acute PDGF 
stimulation either in the presence of LY294002 (a pharmacological inhibitor of PI3K that 
reduces both PI(3,4)P2 and PI(3,4,5)P3) or DMSO (diluent control). We found that Lpd 
localization at the leading edge in both Pfn1 knockdown cells and R88L-Pfn1 rescue expressers 
is dramatically reduced in response to LY294002 treatment (Fig. 18A-B - diluent control DMSO 
preserves strong VASP and Lpd localization at the leading edge as expected). Consistent with 
these results, overexpression of either GFP-PTEN (phosphatase and tensin homolog deleted on 
chromosome 10 - a dual lipid-protein phosphatase that dephosphorylates D3-PPIs and reduces 
their level) or GFP-PH-AKT (a reporter that binds to D3-PPI including PI(3,4)P2 and should 
therefore act as a competitor for other ligands, such as Lpd, for binding to PPI) also completely 
abolishes the strong Lpd distribution at the leading edge in Pfn1-depleted cells (Fig. 18C - as a 
negative control, expression of GFP maintains the characteristic Lpd-rich lamellipodial rim as 
expected). Based on these data demonstrating the sensitivity of membrane targeting of Lpd to 
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D3-PPI perturbation, we speculated that loss of Pfn1 expression might enhance Lpd-targeting to 
the lamellipodial tip through influencing PI(3,4)P2 content at the membrane of the leading edge. 
To test this, we examined PI(3,4)P2 distribution at the leading edge between control and Pfn1-
siRNA treated MDA-231 cells either in basal (serum-starved) or various growth factor (EGF, 
PDGF) stimulated conditions by immunostaining. Figures 18D-E demonstrate that cells under 
either siRNA transfected condition exhibit increased PI(3,4)P2 content at the leading edge in 
response to acute EGF/PDGF stimulation; however, Pfn1-depleted cells have significantly higher 
PI(3,4)P2 accumulation at the leading edge compared control cells in response to these various 
growth-factor stimulated conditions. Stronger PI(3,4)P2 presentation at the leading edge in Pfn1-
deficient cells is clearly consistent with enhanced Lpd targeting to the lamellipodial tip in these 
cells. 
It is known that EGF signaling, in particular, plays a key role in breast cancer cell 
migration/invasion in vitro and in vivo [Goswami et al., 2005; Wyckoff et al., 2004; Xue et al., 
2006]. We therefore asked whether loss of Pfn1 expression alters the expression and/or 
activation of EGFR in MDA-231 cells. Immunoblot data in Figure 18F show that EGF-induced 
phosphorylation of EGFR at its Y1164 residue (a measure of EGFR activation) and the overall 
expression level of EGFR are unaffected by silencing of Pfn1. Similarly, the expression level of 
PDGFRβ and PDGF-induced tyrosine phosphorylation of PDGFR (correlates with its activation) 
were found to be similar between control and Pfn1-depleted cells (Fig. 18G-H). Finally, EGF-
dependent phosphorylation of AKT, a downstream signaling that involves PI3K-mediated 
generation of PI(3,4,5)P3, was also found to be comparable between control and Pfn1-siRNA 
treated cells (Fig 16I). These results indicate that Pfn1-depletion induced increase in PI(3,4)P2 
accumulation at the leading edge is not due to altered RTK activation. 
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Figure 18: Loss of Pfn1 expression enhances PI(3,4)P2 accumulation at the leading edge in 
MDA-231 cells. A) LY294002 treatment dramatically delocalizes VASP from the leading edge 
(arrows), while DMSO (diluent control) treated cells show strong lamellipodial distribution of 
VASP as expected. B) PI3K inhibition by 30 min LY294002 treatment delocalizes Lpd from the 
leading edge (arrows) in PDGF-treated Pfn1-knockdown MDA-231 cells without or with R88L-
Pfn1 rescue (DMSO - vehicle control; arrowhead shows Lpd in membrane ruffles). C) 
Expression of either GFP-PTEN or GFP-PH-AKT but not GFP (control) delocalizes Lpd from 
the leading edge (arrow) in Pfn1-deficient cells. D-E) Representative confocal images (panel D; 
inset shows magnified images of regions outlined by the boxes) and bar graph summarizing 
relative intensity (panel E) of PI(3,4)P2 immunostaining at the leading edge in control and Pfn1-
siRNA treated MDA-231 cells either in basal (serum-starved) or following 30 minutes of EGF 
and PDGF stimulation (arrows show leading edge). ‘N’ indicates number of cells analyzed in 
each group (**: p<0.01). F) Phosphorylation of EGFR at Y1173 residue and total EGFR level at 
different time-points after EGF stimulation in control and Pfn1-siRNA treated cells (GAPDH 
blot - loading control). G) Relative PDGFR-β expression level between control and Pfn1 siRNA 
treated MDA-231 cells (GAPDH blot – loading control). H) Phosphotyrosine (pY) immunoblot 
showing PDGF-induced phosphorylation of PDGFR in control and Pfn1 siRNA treated cells. I) 
Effect of silencing Pfn1 expression on the level of phospho-AKT (S473) 10 min after EGF 
stimulation (AKT blot - loading control). The scale bar in all images represents 20 µm. 
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5.2 DISCUSSION 
A context-dependent role for Pfn1 in cell migration is becoming increasingly evident based on 
differential response of whole cell motility to Pfn1 depletion depending on the cell type. While 
certain types of normal cells (example: human vascular endothelial cells) show impaired motility 
upon loss of Pfn1 function, the opposite occurs with adenocarcinoma (breast, hepatic) cells and 
even some normal cells such as HMEC. Conventional principle of action of Pfn1 through its 
actin and polyproline interactions facilitating membrane protrusion during cell migration cannot 
explain the hypermotile response of breast cancer cells and HMEC enabled in the absence of 
Pfn1. We here describe a novel mechanism of Pfn1-dependent regulation of breast cancer cell 
migration involving its PPI interaction and using Lpd, a PPI-binding Ena/VASP ligand, as a 
mediator. 
Using a knockdown-knockin strategy, we demonstrated that two important phenotypic 
characteristics of MDA-231 cells associated with Pfn1-depletion including hypermotile behavior 
and strong distribution of Lpd/VASP at the lamellipodial tip are completely abolished by GFP-
Pfn1 re-expression therefore confirming the functional rescuing ability of GFP-Pfn1. Among the 
three mutants of Pfn1, only the PPI binding-deficient form (R88L) fails to rescue these 
phenotypes. We found a striking similarity between R88L-Pfn1 re-expressers and Pfn1-deficient 
cells in terms of their motility speed, average velocity of protrusion and Lpd/VASP distribution 
at the lamellipodial tip and these data provide a direct evidence of Pfn1’s negative regulation of 
Lpd/VASP localization at the leading edge and motility of breast cancer cells predominantly 
through its PPI interaction. Even though the effect of Lpd knockdown on whole cell motility has 
not been previously examined, impaired lamellipodia formation and slower membrane protrusion 
in fibroblasts resulting from Lpd knockdown suggest that Lpd is an important regulator of 
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lamellipodial dynamics [Krause et al., 2004]. The same study also showed that Lpd 
overexpression leads to faster membrane protrusion in fibroblasts which can be suppressed by 
Ena/VASP inhibition further indicating that Ena/VASP plays a key role in Lpd’s regulation of 
membrane dynamics at the leading edge. Ena/VASP proteins bind to and promote elongation of 
barbed ends of actin filaments [Barzik et al., 2005; Pasic et al., 2008]. This has been proposed to 
be the mechanism underlying Ena/VASP-driven actin assembly at the leading edge and 
membrane protrusion. We previously demonstrated Ena/VASP’s involvement in the hypermotile 
response of MDA-231 cells induced by Pfn1 downregulation [Bae et al., 2009]. The present 
study showed Lpd’s role in VASP recruitment to the lamellipodial tip, regulation of actin 
assembly at the leading edge/membrane protrusion and overall migration in Pfn1-deficient cells. 
These findings taken together with additional evidence of Lpd’s and Ena/VASP’s involvement in 
the hypermotile response of R88L-Pfn1 expresser are supportive of Pfn1’s negative regulation of 
breast cancer cell motility through Lpd and in turn modulating Ena/VASP function at the leading 
edge. Whether Lpd has an additional contribution to the hypermotile response of Pfn1-
knockdown cells in an Ena/VASP–independent manner is not clear at this point. 
An interesting finding of the present study is the differential sensitivity of control vs Pfn1 
knockdown MDA-231 cells to Lpd depletion. We showed that even though Lpd suppression 
alone can reduce the overall flare of protrusion in MDA-231 cells, this phenotype is rescued 
when cells are seeded on collagen-coated substrate and therefore, it is not surprising that Lpd 
knockdown does not have any significant impact on the overall motility of MDA-231 cells 
assessed on collagen-coated substrate. Pfn1-deficient deficient cells show a more severe 
phenotype in terms of lamellipodia formation and motility when subjected to Lpd depletion. 
Although the underlying reason is not clear, one possibility is that Lpd deficiency can be 
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compensated by RIAM-1 (Rap-interacting adaptor molecule), a Lpd-homolog that also binds to 
membrane PPI, Pfn1 and Ena/VASP proteins like Lpd [Lafuente et al., 2004]. Given that RIAM-
1 regulates cell adhesion/spreading through actin organization and integrin activation, 
compensatory action of RIAM-1 might be more pronounced on adhesion promoting substrate 
such as on collage-coated tissue-culture substrate as used in our motility experiments. If RIAM-
induced actin organization at the leading edge, at least, partially requires the involvement of 
Pfn1, cells lacking Pfn1 would also be expected to be hypersensitive to Lpd depletion as seen in 
our study. This will need to be investigated in the future. 
Finally, we here report a novel finding that loss of Pfn1 expression enhances PI(3,4)P2 
presentation at the leading edge which clearly provides at least one mechanistic explanation for 
how Pfn1 could regulate Lpd distribution at the leading edge. Since Pfn1 can also bind to 
PI(3,4)P2, one cannot absolutely rule out an additional possibility that potential competition 
between Pfn1 and Lpd for PI(3,4)P2 binding could also be relieved upon loss of Pfn1 expression 
thereby further favoring Lpd targeting to the membrane. How might loss of Pfn1 enhance 
PI(3,4)P2 accumulation at the leading edge? Given that PI(3,4)P2 is predominantly generated by 
dephosphorylation of PI(3,4)P2 by SHIP2 and we here show that Pfn1 depletion does not alter 
the activation of EGFR and AKT (a PI(3,4,5)P3-directed event at the downstream of activated 
EGFR), one interesting possibility is that Pfn1’s binding to PI(3,4,5)P3 somehow sterically 
blocks SHIP2’s access to PI(3,4,5)P3 and hence prevents PI(3,4,5)P3’s turnover to PI(3,4)P2. This 
is not completely unreasonable since PI(4,5)P2 hydrolysis by PLCγ (phospholipase-Cγ) has been 
previously shown to be inhibited by PPI-interaction of Pfn1, at least, in vitro [Sohn et al., 1995; 
Goldschmidt-Clermont et al., 1990]. Our future studies revealing how perturbation of Pfn1 
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affects the different PPI turnover pathways in response to RTK activation will provide further 
mechanistic insights into these biochemical events. 
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6.0  CONCLUSIONS 
This work leads to a new paradigm of motility regulation by cytoskeletal molecules with pluri-
ligand docking sites involving signaling cascade at the membrane. We have shown that this is 
how Pfn1, a generally considered pro-migratory molecule, can also inhibit cell motility by 
altering docking of other proteins at the membrane-cytosol interface, and this action is modulated 
by phospholipid interaction of Pfn1. The model we propose is in contrast to conventionally 
presented Pfn1’s role in cell motility primarily through its actin and polyproline interactions. 
Based on this study, an intriguing hypothesis could be that Pfn1 affects cell migration through 
two pathways: a traditional pro-migratory pathway involving its direct action on actin 
polymerization at the leading edge through its actin and polyproline interactions, and an anti-
migratory pathway involving suppression of PI(3,4)P2-dependent leading edge targeting of pro-
migratory complexes such as Lpd/VASP which is strictly regulated by PPI interaction of Pfn1. It 
is the relative contribution of these two opposing pathways which would ultimately define 
whether Pfn1 promotes or limits cell migration. Since the molecular environment of various PPI 
may vary from cell-type to cell-type, Pfn1-dependent modulation of cell motility through its PPI 
interaction could explain its context-dependent role in cell motility. 
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6.1 FUTURE DIRECTIONS 
6.1.1.  To investigate whether Lpd/VASP plays a role in breast cancer metastasis when 
Pfn1 expression is attenuated 
Previous in vivo study from our laboratory demonstrate that overexpressing Pfn1 expression 
inhibits micro-metastasis of MDA-231 breast cancer cells in nude mice [Zou et al., 2007]; 
however, this study did not provide mechanistic insights on how Pfn1 overexpression limits 
migration and invasion of breast cancer cells in vivo. Recent in vitro studies show that 
overexpression of Pfn1 significantly suppresses breast cancer cell migration; conversely, limiting 
Pfn1 expression results in enhanced motility of MDA-231 breast cancer cells [Roy et al., 2004; 
Zou et al., 2007; Bae et al., 2009]. My previous in vitro studies further reveal that significantly 
increased motility of Pfn1-depleted MDA-231 breast cancer cells is through membrane targeting 
of Lpd/VASP complex at the protruding leading edge [Bae et al., 2009] suggesting that 
Lpd/VASP complex at the leading edge plays a role in membrane dynamics and overall breast 
cancer cell migration. However, whether the lamellipodial targeting of the Lpd/VASP complex 
can modulate the hyperinvasiveness (hypermetastasis) of MDA-231 breast cancer cells in vivo 
has not yet been investigated. Since surrounding microenvironment of tissue or matrix in vivo 
has an important factor on tumor cell invasion, I would like to extend my in vitro system to in 
vivo animal experiments.   
To determine the importance of Lpd/VASP complex in metastatic ability of Pfn1-
depleted MDA-231 cells on tumor metastasis, xenograft experiments will be performed with 
Pfn1 knockdown cells with or without co-suppression of Lpd or co-expression Ena/VASP 
mistargeting construct. Based on previous motility data, I expect that inhibiting Lpd/VASP 
 78 
function should dramatically reduce metastasis of Pfn1-depleted MDA-231 cells. If true, 
perturbing Pfn1 and Lpd/VASP expression levels could prove to be a good molecular strategy 
for limiting metastasis of breast cancer cells.    
 
6.1.2 To determine whether Pfn1 regulates the overall turnover and spatiotemporal 
dynamics of PPIs in breast cancer cells 
Pfn1’s interaction with membrane PPIs has mostly been confirmed in vitro and among the 
different PPIs, Pfn1 has been found to bind to PI(4,5)P2, PIP3, and PI(3,4)P2 [Lu et al., 1996]. 
Biochemical experiments with purified constituents initially demonstrated that Pfn1 inhibits 
PLC-mediated PI(4,5)P2 hydrolysis to IP3. Since these experiments were performed with 
purified constituents, determining whether Pfn1 influences PPI metabolism and the functional 
significance of such metabolism has not yet been thoroughly investigated in a cellular context. 
Based on recent observations from our laboratory demonstrating that limiting Pfn1 expression 
dramatically increases leading edge localization of PI(3,4)P2 [unpublished data] and 
overexpressing Pfn1 significantly reduces PIP3 generation in breast cancer cells [Das et al., 
2009], I propose that Pfn1 plays a important role in regulating PPI turnover and consequently 
PPI-dependent downstream signaling.  
To test this working model, I will first determine whether perturbing Pfn1 expression alters PPI 
turnover and the resulting products in MDA-231 breast cancer cells either in a basal or an EGF 
(or PDGF)-stimulated state by immunostaining and TLC-based detection assays. The next goal 
would be a fluorescence-based reporter assay or FRET-based (fluorescence resonance energy 
transfer) assay in real time to visualize the spatiotemporal dynamics of various PPIs at the cell 
membrane in response to growth factor (EGF, PEGF) stimulation in breast cancer cells. Overall, 
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this study will provide mechanistic insights as to whether and how perturbation of Pfn1 
influences the different PPI turnover pathways and dynamics in response to receptor tyrosine 
kinase activation in cells.      
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